Femasys Q2 net loss narrows 2.55% to $4.47 million; net sales drop 18.9% to $331,827
FEMY•Quarterly results
- Femasys posted a Q2 net loss of $4.47 million, or $1.33 per share, versus a year-earlier net loss of $4.59 million.
- Net sales fell 18.9% to $331,827, on lower FemVue sales.
- Research and development expenses climbed 37.6% to $1.95 million, reflecting inventory transition to support commercialization and higher clinical costs.
Financing and outlook
- The company completed a $30 million private placement, with potential proceeds up to $90 million upon full cash exercise of warrants.
- Management said the financing supports U.S. commercialization of FemaSeed Complete and advancement of the U.S. FemBloc clinical program toward approval.
